Umemoto, Kumiko
Takahashi, Hideaki
Morizane, Chigusa
Yamada, Ikuhiro
Shimizu, Satoshi
Shioji, Kazuhiko
Yoshida, Yukio
Motoya, Masayo
Mizuno, Nobumasa
Kojima, Yasushi
Terashima, Takeshi
Uesugi, Kazuhiro
Ueno, Makoto
Furuse, Junji
Akimoto, Tetsuo
Ikeda, Masafumi http://orcid.org/0000-0002-4050-2086
Article History
Received: 27 March 2020
Accepted: 19 November 2020
First Online: 2 January 2021
Compliance with ethical standards
:
: Morizane C has received honoraria for speaking from Novartis, Yakult Honsha, Teijin Pharma, Taiho Pharmaceutical, Eisai and MSD, advisory board from Yakult Honsha, Novartis, Taiho Pharmaceutical and Abbvie, and research grants from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma AstraZeneca and Merck biopharma. Shimizu S has received research grants from Sumitomo Dainippon, AstraZeneca, Taiho Pharmaceutical, NanoCarrier, Eisai, Baxalta Japan Limited and Incyte Corporation. Mizuno N has received research grants from Yakult Honsha, Novartis, Taiho Pharmaceutical, AstraZeneca, NanoCarrier, Dainippon Sumitomo Pharma, ASLAN PharmaceuticaIs, Incyte, Pharma Valley Center and Eisai, and honoraria for speaking from Yakult Honsha, Novartis, Taiho Pharmaceutical, Teijin Pharma and MSD. Kojima Y has received honoraria for speaking from Chugai, Sanofi, Bristol-Myers Squibb, and is an independent data monitoring committee of Astra Zeneca. Ueno M has received honoraria from Taiho Pharmaceutical, Yakult Honsha, AstraZeneca, Novartis, Eli Lilly, Teijin Pharma, Shire, Ono Pharmaceutical and Merck Serono, and research grants from Taiho Pharmaceutical, Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical, MSD, Merck Serono, NanoCarrier, Dainippon Sumitomo Pharma, Incyte, ASLAN Pharmaceuticals and Yakult Honsha. Furuse J has received research grants from funding agencies from Ono Pharmaceutical, MSD, Sumitomo Dainippon, J-Pharma, Yakult Honsha, AstraZeneca, Daiici Sankyo, Daiichi Sankyo, Eisai, Bayer, Pfizer, NanoCarrier, Kyowa Hakko Kirin, Chugai, Sanofi, Takeda, Mochida, Astellas Pharma and Eli Lilly, honoraria for speaking at symposia from Eisai, Bayer, Taiho, Ono Pharmaceutical, Novartis, Yakult, Teijin, Shionogi, EA pharma, Eli Lilly, Chugai, Mochida, Nihon Sevier, Sanofi, Fujifilm, Toyama, Chemical, Nobel pharma, Pfizer Sawai, Daiichi Sankyo, Sumitomo Dainippon, Merck Serono, Nippon Kayaku, MSD, Shire, Kyowa Hakko Kirin and is the position on advisory board to Eisai, Fujifilm, Ono Pharmaceutical, Yakult, MSD, Merck Bio, J-Pharma, MSD, Chugai, Taiho, Nihon Servier, AstraZeneca, Abbvie, Astellas. Ikeda M has received honoraria for speaking from Novartis Pharma, Bayer, Eisai, Taiho Pharmaceutical, Eli Lilly Japan, Sumitomo Dainippon Pharma, Teijin Pharma, MSD, Mylan, Chugai Pharmaceutical, Otsuka Pharmaceutical, Yakult, Nihon Servier, Astellas and is the position on advisory board to Bayer, Eisai, Eli Lilly, Novartis Pharma, Chugai Pharmaceutical, Nihon Servier, Ono Pharmaceutical, AstraZeneca and Micron. Umemoto K, Takahashi H, Yamada I, Shioji K, Yoshida Y, Motoya M, Terashima T, Uesugi K, and Akimoto T have no conflict of interest to declare.
: This study was conducted in accordance with the principles laid down in the 1964 Declaration of Helsinki and its later amendments, and the protocol was approved by the Ethics Committee of National Cancer Center (Approval No. 2016-092) and all the institutions participating this study. Approval for review of the hospital records was obtained from the Institutional Review Board of the National Cancer Center and the need for informed consent from the patients was waived in view of the retrospective nature of the study.